Pan-HER, an Antibody Mixture Simultaneously Targeting EGFR, HER2, and HER3, Effectively Overcomes Tumor Heterogeneity and Plasticity

• Published in: Clinical cancer research Vol. 21; no. 18; pp. 4110 - 4122
• Main Authors: Jacobsen, Helle J, Poulsen, Thomas T, Dahlman, Anna, Kjær, Ida, Koefoed, Klaus, Sen, Jette W, Weilguny, Dietmar, Bjerregaard, Bolette, Andersen, Christina R, Horak, Ivan D, Pedersen, Mikkel W, Kragh, Michael, Lantto, Johan
• Format: Journal Article
• Language: English
• Published: United States 15.09.2015
• Subjects: Animals; Antibodies, Monoclonal, Humanized - chemistry; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm - immunology; ErbB Receptors - chemistry; ErbB Receptors - immunology; Gene Expression Regulation, Neoplastic; Humans; Ligands; Mice; Mice, Nude; Neoplasms, Experimental - drug therapy; Receptor, ErbB-2 - chemistry; Receptor, ErbB-2 - immunology; Receptor, ErbB-3 - chemistry; Receptor, ErbB-3 - immunology; Signal Transduction; Xenograft Model Antitumor Assays

Accumulating evidence indicates a high degree of plasticity and compensatory signaling within the human epidermal growth factor receptor (HER) family, leading to resistance upon therapeutic intervention with HER family members. We have generated Pan-HER, a mixture of six antibodies targeting each of...